CN105126098B - Monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer - Google Patents
Monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer Download PDFInfo
- Publication number
- CN105126098B CN105126098B CN201510465819.XA CN201510465819A CN105126098B CN 105126098 B CN105126098 B CN 105126098B CN 201510465819 A CN201510465819 A CN 201510465819A CN 105126098 B CN105126098 B CN 105126098B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- cell
- invasion
- transfer
- attack
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 33
- 230000009545 invasion Effects 0.000 title claims abstract description 24
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 230000001629 suppression Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 claims abstract description 8
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 4
- 101150044508 key gene Proteins 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 57
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 abstract description 20
- 201000005249 lung adenocarcinoma Diseases 0.000 abstract description 16
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 3
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 abstract description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 abstract description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 abstract description 2
- 230000005012 migration Effects 0.000 abstract description 2
- 238000013508 migration Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 239000003292 glue Substances 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 11
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 10
- 230000012292 cell migration Effects 0.000 description 10
- 239000012531 culture fluid Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000004709 cell invasion Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102100028122 Forkhead box protein P1 Human genes 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003667 anti-reflective effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer.Monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer.Described monoclonal antibody NJ001 1 is secreted by the hybridoma cell strain NM001 1 that preserving number is CCTCC NO:C201172.Monoclonal antibody NJ001 1 can effectively suppress migration and the invasion and attack of lung adenocarcinoma cell, and can dramatically increase TIMP 3mRNA and protein expression.Under monoclonal antibody NJ001 1 effect, in lung adenocarcinoma cell core, monoclonal antibody NJ001 1 specific antigen can be combined with transcription factor FOXP1, suppresses its transcripting suppressioning action to TIMP 3 gene promoter area.
Description
Technical field
The invention belongs to field of biological medicine, relate to monoclonal antibody NJ001-1 in preparation suppression NSCLC invasion and attack and transfer
In application.
Background technology
The invasion and attack of pulmonary carcinoma and transfer are its pernicious mark and feature, are also to affect treatment in patients with lung cancer effect and cause patient
Dead main reason.Pulmonary carcinoma can be divided into small cell lung cancer and nonsmall-cell lung cancer (Non-small-cell Lung
Cancer, NSCLC), wherein NSCLC accounts for 85%, most commonly seen with adenocarcinoma of lung again in NSCLC.NSCLC onset is hidden, development
Rapidly, poor prognosis, the median survival interval of therapist is not only 4～5 months, and within 1 year, survival rate is about 10%, and 5 years survival rates are not
Foot 5%.Have there is metastasis (IV phase) when clinical first visit in most NSCLC patients, and chemotherapeutic drug therapy effect is the most undesirable.
At present, non-small cell lung cancer cell occurs the molecular mechanism of transfer to illustrate the most completely, and the most also lacks specificity height, pin
The medicine of the suppression lung carcinoma cell transfer strong to property.Therefore, explore the molecular mechanism of invasion of lung cancer transfer, find and develop
The active drug for the treatment of invasion of lung cancer transfer and therapy approach, be the key point of pulmonary carcinoma molecular biology research.
The Invasion and Metastasis of tumor is a multi-step, multistage, multipath, relates to the complex process that polygenes changes.Have
Research shows, in cancer cell invasion and transfer process, multiple signal paths can be activated, such as RAS/MAPK path, Akt/
PI3K path and ERK path etc., so that cell produces biological characteristic and the behavior of tumor cell.Under normal circumstances, tumors invading
Attacking and shifting is the process of an active, needs tumor cell jointly to participate in tumor mechanism composition, often includes three steps: tumor
Cell sticks with extracellular matrix；Tumor cell release or induction release multiple protein hydrolytic enzyme, degradation of cell epimatrix；Fall
The tumor cell solving region shifts under the guiding of chemotactic factor, tumor cell induction of vascular in target tissue on this basis
Formed, resist Host Anti-tumor Immunity, form metastasis the most a long way off.
Expression of TIMP-3 (TIMP-3) is the non-solubility egg that one combines extracellular matrix (ECM)
In vain.TIMP-3 participates in growth and the process of reconstruction of normal structure, has also assisted in the generation of numerous disease.TIMP-3 mono-aspect is permissible
Stimulate fibroblast proliferation, the most but the apoptosis of inducing malignant tumor cell.Owing to TIMP-3 can be with 1: 1 molecular ratios
With matrix metalloproteinase (MMPs) Non-covalent binding, the activity of suppression MMPs, therefore TIMP-3 has suppression tumor growth, invasion and attack
With the effect of transfer, in tumor tissues, TIMP-3 expression lowers or loses the process by promoting tumor.As can be seen here, base
Matter metalloproteases (MMPs) and inhibitor (TIMP) thereof are the key factors of regulation and control nonsmall-cell lung cancer invasive ability.
The process that malignant cell sends out other positions from original site through approach such as lymph, blood, body cavitys is swollen
The transfer of tumor.The transfer of malignant cell is that it is different from one of Normocellular feature, is the biological property of itself.
The transfer of tumor is that it jeopardizes host's life and affects the main cause of therapeutic effect.Malignant cell can shift, and it is former
All many different, such as because being that it has from normal cell: the forfeiture of adjusting and controlling growth mechanism, fluidity of plasma membrane change, carefully
The change of born of the same parents' motor capacity, cell atypia increase, adhesiveness change, cell polarity change etc..In different tumors, its cell
Characteristic is incomplete same, and therefore its transfer ability also differs, even if in same tumor body, it is also possible to exists and has different transfer
The cell subsets of potential.The at present research of anti-metastasis drug is thin mainly for tumor in the mechanism of neoplasm metastasis and transfer process
Born of the same parents, the various changes of body tissue have carried out many research, but due to the polytropy of neoplasm metastasis itself, complexity, shadow
The multiformity of the factor of sound, and the restriction of research means, up to the present, not yet find that the definite malignant tumor that can control turns
Mobile medicine.
At present, although the antitumor drug being applied to clinic can suppress tumor growth to a certain extent, promote that tumor is thin
Born of the same parents' apoptosis, but the invasion and attack and transfer to tumor cell there is no significant inhibitory action.The apoptosis of tumor cell and Invasion and Metastasis
It is two pathophysiological processes that molecular mechanism is different.The approach of regulating cell apoptosis mainly includes mitochondria pathway, endoplasmic reticulum
Approach and death receptor pathway *.But, tumor cell invasion shifts most and matrix metalloproteinase and the gene of mortifier thereof
Expression, Epithelial and stromal etc. are relevant.As a example by the platinum series antineoplastic medicament of clinical practice-cisplatin, carboplatin etc., although platinum medicine
Can significantly inhibit tumor proliferation, anticancer spectrum is relatively wide, but its invasion and attack that cannot suppress tumor and transfer.Therefore, it is possible to promotion tumor
Apoptosis, the medicine of suppression tumor growth or antibody might not can be used in suppressing tumor invasion and transfer.Develop for
The medicine of Malignant tumor of bonal metastasis will become the important channel extending tumor patient life span, improving oncotherapy effect.
Summary of the invention
It is an object of the invention to the above-mentioned deficiency for prior art, it is provided that monoclonal antibody NJ001-1 is in preparation suppression
Application in the medicine of NSCLC invasion and attack and transfer.
The purpose of the present invention can be achieved through the following technical solutions:
The application in the medicine of preparation suppression NSCLC invasion and attack and transfer of monoclonal antibody NJ001-1.Described monoclonal
Antibody NJ001-1 is by the hybridoma cell strain NM001-1 secretion that preserving number is CCTCC NO:C201172.
The key gene that monoclonal antibody NJ001-1 is acted in suppression NSCLC invasion and attack and transfer is being made as target spot
Application in the medicine of standby suppression NSCLC invasion and attack and transfer.
The key gene that described monoclonal antibody NJ001-1 is acted in suppression NSCLC invasion and attack and transfer is preferably compiled
Code transcription factor FOXP1.
The preparation method of monoclonal antibody NM001-1 of the present invention is shown in CN102391992B.
Beneficial effect:
Monoclonal antibody NJ001-1 specific recognition can be positioned at NSCLC cytoplasm and the SP70 antigen on cell membrane, tool
There is the induction apoptotic effect of NSCLC, and the invasion and attack and transfer to tumor cell there is also potential effects.Monoclonal antibody
NJ001-1 can effectively suppress migration (Fig. 1) and the invasion and attack (Fig. 2) of lung adenocarcinoma cell, and can dramatically increase TIMP-3mRNA and egg
White expression (Fig. 3).Under monoclonal antibody NJ001-1 effect, NJ001-1 specific antigen energy and transcription factor in lung adenocarcinoma cell core
FOXP1 combines, and suppresses its transcripting suppressioning action to TIMP-3 gene promoter area.
Accompanying drawing explanation
Fig. 1 cell scratch experiment detection lung adenocarcinoma cell transfer ability
A: monoclonal antibody NJ001-1 processes SPC-A1 cell 0h and 48h " cut " figure；
B: monoclonal antibody group compares with matched group SPC-A1 cell migration distance；
* compare between monoclonal antibody group and corresponding matched group, * P < 0.05, * * P < 0.01, * * * P < 0.001.
Fig. 2 Transwell experiment detection lung adenocarcinoma cell invasive ability
Fig. 3 monoclonal antibody NJ001-1 induction TIMP-3 expresses
Fig. 4 monoclonal antibody NJ001-1 specific antigen (50kDa) and FOXP1 interacts
The preservation information of biological material specimens
Hybridoma cell strain NM001-1 was preserved in China typical culture collection center, preservation ground on August 31st, 2011
Location is Wuhan, China, Wuhan University, and preserving number is CCTCC NO:C201172.
Detailed description of the invention
Embodiment 1
1, cell migration detection
Collection is in the lung adenocarcinoma cell SPC-A-1 of exponential phase and makes single cell suspension, with 2 × 105Cells/well adds
Enter in 6 porocyte culture plates, incubated overnight, inhale and abandon culture supernatant, and wash one time with Hank ' s liquid 500 μ l/ hole.Antibody group (50 μ
G/mL, 100 μ g/mL and 150 μ g/mL tri-groups): every hole adds monoclonal antibody NJ001-1 solution, and final concentration is respectively 50 μ g/mL, 100 μ
G/mL and the 150 every holes of μ g/mL；Matched group (0 μ g/mL): every hole adds 20ml culture fluid.Cultivate 24h and 48h after intervention, be used for
Cell migration detects.Often group sets 3 parallel holes, and experiment is repeated 3 times.
2, cell migration ability (scratch experiment) detection
Principle: be when cell grows to be fused into monolayer state, one clear area of artificial manufacture on the cell monolayer merged
Territory, is referred to as " cut " (Wound).The cell of scratching edge can progress into white space makes " cut " to heal (Healing).Base
This step includes acquisition and the process of later data of image during the manufacture of " cut ", cell migration.
Operating process:
(1) by 2 × 105Cells/well adds in 6 porocyte culture plates, and incubated overnight treats that cell grows to Fusion Strain.Number
Measure and be advisable to be paved with at the bottom of plate after adherent；
(2) four roads orthogonal " well " stroke is marked with 10 μ l import rifle heads after sterilization at clean cell surface
Trace；
(3) suck cell culture fluid, use PBS washed cell 3 times, wash away the cell debris that cut produces；
(4) select the cut visual field, be marked, and under microscope, carry out observation take pictures；
(5) 6 porocyte culture plates are put into cell culture incubator cultivate, take out after 24h and 48h and take pictures；
(6) cut healing state calculates with the spacing ratio of cell wound healing spacing with cell cut.
Result:
The monoclonal antibody NJ001-1 of 50 μ g/mL, 100 μ g/mL and 150 μ g/mL concentration acts on adenocarcinoma of lung SPC-A-1 cell 48h
After, " cut " healing ability reduces, i.e. compared with matched group (without monoclonal antibody NJ001-1 process), monoclonal antibody group cut blank space
Distance is wider.By measuring monoclonal antibody group and " cut " width of matched group 0h and 48h, calculate SPC-A-1 cell migration distance, than
Respectively organize the difference of SPC-A-1 cell migration ability.Result shows, monoclonal antibody group SPC-A-1 cell migration ability is by different journeys
The suppression of degree, after wherein 100 μ g/mL and 150 μ g/mL monoclonal antibody NJ001-1 act on SPC-A1, cell migration ability reduces, with right
Compare according to group and there is significant difference (P value is respectively less than 0.05)；After 50 μ g/mL monoclonal antibody NJ001-1 act on SPC-A1, cell moves
Shifting distance diminishes, but no difference of science of statistics compared with matched group.The above results shows, monoclonal antibody NJ001-1 can suppress adenocarcinoma of lung thin
Born of the same parents migrate.Low dosage monoclonal antibody NJ001-1 is to the inhibitory action of lung adenocarcinoma cell transfer ability inconspicuous, but along with monoclonal antibody
The increase of NJ001-1 concentration, the transfer ability of lung adenocarcinoma cell is gradually lowered, prompting monoclonal antibody NJ001-1 energy dose dependent
Lung adenocarcinoma cell is migrated and plays inhibitory action.
Embodiment 2
(1) cell invasion detection
Collection is in SPC-A-1 and A549 of exponential phase and makes single cell suspension, with 8 × 104Cells/well adds 24
In porocyte culture plate.Antibody group (50 μ g/mL, 100 μ g/mL and 150 μ g/mL tri-groups): every hole mistress adds monoclonal antibody NJ001-1
Solution, final concentration is respectively 50 μ g/mL, 100 μ g/mL and the 150 every holes of μ g/mL；Matched group (0 μ g/mL): every hole adds 500 μ l
Culture fluid.Cultivate 24h after intervention, detect for cell invasion.Often group sets 3 parallel holes, and experiment is repeated 3 times.
(2) cell invasion ability (Transwell experiment) detection
Principle: put in culture plate by transwell cell, little indoor are referred to as upper room, are referred to as lower room, upper room in culture plate
Interior interpolation culture supernatants, lower indoor interpolation lower floor culture fluid, levels culture fluid is separated by with film.By cell kind in upper indoor,
Owing to film has permeability, the composition in lower floor's culture fluid can have influence on the cell of indoor, such that it is able to research lower floor cultivates
The impact of composition cell growth in liquid, motion etc..Select the film of different materials and aperture, can carry out co-culturing, cell
The research of the multiple aspects such as chemotactic, cell migration, cell invasion.
Operating process:
(1) in the cell of Transwell 24 porocyte culture plate, add 60 μ l matrigel (ECM gel) diluents, base
Matter glue is 1:9 with the dilution ratio of serum-free RPMI-1640 culture fluid；
(2) Transwell 24 porocyte culture plate is put into 37 DEG C of cell culture incubators, make matrigel natural coagulation；
(3) lung adenocarcinoma cell being resuspended in serum-free RPMI-1640 culture fluid, every cell adds 1 × 105～1 × 106Carefully
Born of the same parents (specifically change because cell-penetrating ability is different), and upper indoor serum-free RPMI-1640 culture fluid cumulative volume is 200 μ l；
(4) it is grouped according to cell, at the lower indoor addition 500 μ l RPMI-1640 culture fluid containing 10%FBS, wherein monoclonal antibody
The concentration of NJ001-1 is respectively 0 μ g/mL, 50 μ g/mL, 100 μ g/mL and 150 μ g/mL；
(5) Transwell 24 porocyte culture plate is put into cell culture incubator cultivate, take out after 24h；
(6) being wiped by the cell of little for transwell chamber internal surface with cotton swab, cell outer surface cellular fixed by 95% ethanol
20min；
(7) with 1% Crystal Violet Dye, cell outer surface cellular is dyeed, 20min；
(8) PBS of pre-cooling cleans cell outer surface cellular 3 times, sucks residual liquid from little chamber internal surface；
(9) Olympus Optical basis of microscopic observation penetrates the cell of matrigel, and counting of taking pictures.
Result:
The monoclonal antibody NJ001-1 of 50 μ g/mL, 100 μ g/mL and 150 μ g/mL concentration act on lung adenocarcinoma cell (SPC-A1 and
A549), after 24h, the lung adenocarcinoma cell quantity of invasion and attack is occurred to significantly reduce, compared with matched group (without monoclonal antibody NJ001-1 process)
There is significant difference (P value is respectively less than 0.05)；Along with the increase of monoclonal antibody NJ001-1 concentration, there is the adenocarcinoma of lung of invasive ability
Cell quantity substantially reduces.The above results shows, monoclonal antibody NJ001-1 can significantly inhibit the invasive ability of lung adenocarcinoma cell, and
This inhibitory action has obvious dose dependent.
Embodiment 3 TIMP-3 detection of expression
RT-PCR:
1) sample prepares
Discarding culture fluid in culture plate, every hole adds 700 μ l Trizol reagent, the most repeatedly blows and beats cell with Trizol,
Carry out digesting, cracking.After cell is completely dissolved, collection solution is in going in enzyme EP pipe ,-70 DEG C of preservations.
2) RNA extracts
(1) desk-top high-speed refrigerated centrifuge is regulated to 4 DEG C；
(2) cell mass of Trizol has been added from-70 DEG C of refrigerators taking-ups；
(3) blow and beat gently with rifle head after cell mass dissolves or whirlpool concussion mixes, whirlpool concussion 1min；
(4) room temperature (15～25 DEG C) places 5min；
(5) add 140 μ l chloroforms, cover tightly lid gently, acutely shake 15s；
(6) room temperature stands 2～3min；
(7) 4 DEG C of 12000g × 15min, are adjusted to room temperature by centrifuge；
(8) upper strata aqueous phase is carefully inhaled new EP pipe (offer) is provided, add the dehydrated alcohol of 1.5 times of volumes (about 525 μ l),
Blow and beat mixing gently with rifle head, carry out next-step operation immediately；
(9) 700 μ l are inhaled in post, froth lid, room temperature (15 DEG C～25 DEG C), 10000rpm × 15sec abandons liquid, if liquid
Body cumulative volume then repeats step (9) more than 700 μ l；
(10) add 700 μ l Buffer RWT to pillar film, build lid gently, room temperature (15 DEG C～25 DEG C),
10000rpm × 15sec abandons liquid；
(11) add 500 μ l Buffer RPE to pillar film, build lid gently, room temperature (15 DEG C～25 DEG C),
10000rpm × 15sec abandons liquid；
(12) add 500 μ l Buffer RPE to pillar film, build lid gently, room temperature (15 DEG C～25 DEG C),
10000rpm × 2min abandons liquid；
(13) it is carefully removed from pillar to manage to new 2ml EP, high speed centrifugation 1min；
(14) pillar is moved to new 1.5ml EP pipe, on absorption 30～50 μ l ddH2O to pillar film, build pipe gently
Lid, 10000rpm × 1min；
(15) if concentration 30 μ g, step (15) is repeated.
3) cDNA synthesis (uses Japan TAKAR company PrimeScriptTM RT Master Mix(Perfect Real
Time) Reverse Transcription box)
(1) reverse transcription reaction system:
(2) reverse transcription reaction is carried out in PCR amplification instrument: 16 DEG C of 30min, 42 DEG C of 30min, 85 DEG C of 5min；After reaction terminates
Place it in the most stand-by or-70 DEG C of preservations.
4) PCR detection
(1) reaction system (10 μ l):
Primer sequence: TIMP-3 forward primer: 5 '-CCTGCTGACAGGTCGCGTCT-3 '；Downstream primer: 5 '-
TCCAGAGACACTCGTTCTTG-3′.MMP-7 forward primer: 5 '-TCGAGACTTACCGCATATTAC-3 '；Downstream primer:
5′-TCCAGCGTTCATCCTCAT-3′；β-actin is as reference gene, forward primer: 5 '-TGGCCCCAGCACAATGAA-
3′；Downstream primer: 5 '-CTAAGTCATAGTCCGCCTAGAAGCA-3 '.
(2) amplified reaction is carried out in PCR amplification instrument: 1 circulation of 95 DEG C of 10min, 95 DEG C of 15sec, 60 DEG C of 1min, 45
Circulation；React after terminating according to gained CT value application 2-△△CTMethod calculates the relative expression quantity of miRNA.
Western Blot method detection protein expression
(1) glue plate is prepared
Glass plate is cleaned gently, again with distilled water flushing after rinsing well with tap water, by thickness after drying with detergent liquid
Aliging bottom the glass plate of thin both sides, pressure equalizes, and is installed on gum-making rack；
(2) according to the form below preparation separation gel and concentration glue
When joining glue, by table order reagent adding, TEMED is slowly injected into glass plate interlayer after adding mixing immediately along side.Point
It is 4ml/ block from the glue amount of recording, stays concentration glue desired height (longer 1cm than comb length), add distilled water and flatten, stand 60min
(room temperature is long-time compared with low time delay) is polymerized.Toppling over glass plate and remove distilled water, filter paper blots, it is impossible to touch gel.Join by upper table
System concentrates glue and irrigates, concordant with the thin glass of outer layer, inserts comb from lopsidedness, prevents bubble from producing, and stands 30min and makes
Its polymerization, preservative film adds appropriate ddH24 DEG C of refrigerator overnight are put after O parcel gel；
Glass plate moves into electrophoresis tank, and inside groove fills it up with electrophoretic buffer, sees whether leakage, and removing attaches to gel
The bubble of bottom, otherwise affects electric current unimpeded, takes out comb, it is to avoid loading wells tears；
(3) sample treatment and loading
Adding 2 × electrophoresis sample buffer of equivalent in protein sample, boil 5min after mixing, 4 DEG C, 12000rpm is centrifuged
5min, takes sample and adds loading wells, and each porin amount is impartial.Add molecular weight standard protein Marker for comparison simultaneously；
(4) electrophoresis
Under 60V voltage, electrophoresis changes voltage when all leaving loading wells to sample to separation gel interface is 80V, continues electrophoresis and fits
When after the time, power-off stops electrophoresis；
(5) transferring film
The preparation carrying out transferring film at the end of SDS-PAGE is fast (prepares ice and ice chest, transferring film buffer pre-cooling, PVDF
Film, puts into sponge and filter paper in transferring film buffer and soaks)
↓
Pry open glass plate gently, judge the position of purpose fragment according to Marker, cut glue, immerse transferring film buffer
↓
Size according to glue cuts correspondingly sized pvdf membrane, and film is bigger, it is impossible to little and shear angle carries out labelling
↓
Pvdf membrane methanol activates 1min, then rinses 1min with transferring film buffer
↓
Install the interlayer of film and glue by the order of black glue tunica albuginea, install electrophoresis transferring groove by the order of glue negative electrode film positive pole
↓
Electrophoresis transferring groove is put in ice, puts ice bag and add the transferring film buffer of pre-cooling in groove, and under constant current state, 100mA turns
Film, transferring film electric current and time can regulate according to molecular size range
↓
Transferring film carefully takes off film after terminating, 5% defatted milk powder (TBST preparation) room temperature closes 3h
↓
Adding an anti-reflective and answer (antibody is diluted by respective description), 4 DEG C overnight.
↓
1 × TBST washes film, and 15min changes and once washes film buffer, totally 3 times
↓
It is anti-to add two, room temperature reaction 1h, and period slowly shakes on shaking table
↓
1 × TBST washes film, and 15min changes and once washes film buffer, totally 3 times
↓
After blotting film buffer with filter paper, film is put on sealed membrane
↓
Add ECL luminescence AB mixing liquid, react 3min, operating process notes lucifuge
↓
Putting in magazine and be exposed in darkroom, time of exposure is from 10s to 1h
↓
Development, notes holding developing time, rinses, fixing transparent to film
↓
Gel imaging system is utilized to gather image and preserve
Result:
The monoclonal antibody NJ001-1 of 50 μ g/mL, 100 μ g/mL and 150 μ g/mL concentration act on lung adenocarcinoma cell (SPC-A1 and
A549) after 24h, TIMP-3mRNA and protein expression can be dramatically increased, tool compared with matched group (without monoclonal antibody NJ001-1 process)
There is significant difference (P value is respectively less than 0.05).
Embodiment 4 monoclonal antibody NJ001-1 specific antigen and the interaction of nuclear factor FOXP1
Co-immunoprecipitation:
Monoclonal antibody NJ001-1 processes after SPC-A1, with the SCP-A1 Nuclear extract of total amount 1mg and POXP1 antibody (3 μ g) or
Rabbit igg and protein A-Agarose are hatched.FOXP1 complex SDS buffer solution elution, it is thus achieved that albumen carries out Western
Blot detects.
Result:
Under monoclonal antibody NJ001-1 effect, monoclonal antibody NJ001-1 specific antigen energy and transcription factor in lung adenocarcinoma cell core
FOXP1 combines, and suppresses its transcripting suppressioning action (Fig. 4) to TIMP-3 gene promoter area.
Claims (2)
1. monoclonal antibody NJ001 application in the medicine of preparation suppression NSCLC invasion and attack and transfer；Wherein, described Dan Ke
Grand antibody NJ001 is by the hybridoma cell strain NM001-1 secretion that preserving number is CCTCC NO:C201172.
2. the key gene that monoclonal antibody NJ001 is acted in suppression NSCLC invasion and attack and transfer presses down in preparation as target spot
Application in the medicine of NSCLC processed invasion and attack and transfer；Described key gene is encoding transcription factors FOXP1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510465819.XA CN105126098B (en) | 2015-07-31 | 2015-07-31 | Monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510465819.XA CN105126098B (en) | 2015-07-31 | 2015-07-31 | Monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105126098A CN105126098A (en) | 2015-12-09 |
| CN105126098B true CN105126098B (en) | 2016-12-28 |
Family
ID=54711904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510465819.XA Active CN105126098B (en) | 2015-07-31 | 2015-07-31 | Monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105126098B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109939234A (en) * | 2019-03-15 | 2019-06-28 | 中国科学院上海高等研究院 | The purposes of FOXP1 gene and its inhibitor in preparation inhibition lung cancer metastasis drug |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102391992B (en) * | 2011-11-03 | 2012-08-29 | 潘世扬 | Monoclonal antibody for resisting human NSCLC and application of monoclonal antibody |
-
2015
- 2015-07-31 CN CN201510465819.XA patent/CN105126098B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105126098A (en) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rickard et al. | Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response | |
| Wang et al. | Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma. | |
| Jensen et al. | Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells | |
| Wu et al. | Upregulation of SCNN1A promotes cell proliferation, migration, and predicts poor prognosis in ovarian cancer through regulating epithelial–mesenchymal transformation | |
| Huang et al. | IL‑33/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway | |
| CN107582550A (en) | Application of the QAB-149 in colorectal cancer is treated | |
| US20220125877A1 (en) | Method for treating colorectal cancer | |
| CN108685921A (en) | A kind of application of the quinoline of N isosteres iridin in medicines resistant to liver cancer | |
| CN105126098B (en) | Monoclonal antibody NJ001 1 application in the medicine of preparation suppression NSCLC invasion and attack and transfer | |
| Wang et al. | FGF19 contributes to tumor progression in gastric cancer by promoting migration and invasion | |
| Zhang et al. | Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma | |
| CN103695423B (en) | Regulation and control YAP and/or TEAD and/or the new application of RHAMM expression material | |
| CN103494803A (en) | New application of dehydrated andrographolide | |
| CN104083368A (en) | Application of G-1 in preparation of G protein coupled receptor 30-based triple negative breast cancer targeting drugs | |
| CN108714149A (en) | Purposes of the garden burnet active constituent in preparing anti-tumor drug | |
| CN105181966B (en) | A kind of MAGE A9 purposes | |
| Peng et al. | TNFR1 regulates ovarian cancer cell tumorigenicity through PIK3CB-p110Beta | |
| CN104958306B (en) | Platinum medicine is preparing the application in treating ovarian cancer to compound Hu 17 alone or in combination | |
| Zhong et al. | Effect of metformin on the proliferation and apoptosis of the renal cancer cell line 786-O and the underlying mechanisms | |
| CN113116917B (en) | Application of 8-Br-cGMP as PKG I activator in preparation of medicine for preventing or treating ovarian epithelial cancer | |
| CN103981186A (en) | Interfering RNA and lentivirus targeted to OLFM4 gene, and application thereof | |
| CN110082536A (en) | A kind of breast cancer cell marker cell factor group and its application | |
| CN108164529A (en) | A kind of micromolecular inhibitor SLD9059 and its application in pharmacy | |
| CN102337332A (en) | Gene and application of protein encoded by gene to preparation of medicine for diagnosing and treating breast cancer | |
| CN109223801A (en) | A kind of new the killing agent of gastric cancer tumor stem cell and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20161111 Address after: Spark Road 210032 Jiangsu province Nanjing city high tech Development Zone No. 10 Dingye biotech building block D Room 308 Applicant after: Nanjing Mclean biological medicine technology Co., Ltd. Address before: 210032, Jiangsu Province, Pukou District, Nanjing hi tech Development Zone, 10 Spark Road, ding industry, 100 Thai biological building, block D, room 306 Applicant before: NANJING RENCHEN BIOTECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| CI01 | Correction of invention patent gazette |
Correction item: Applicant|Address Correct: NANJING MAIKELIN BIOMEDICAL TECHNOLOGY CO., LTD.|Spark Road 210032 Jiangsu province Nanjing city high tech Development Zone No. 10 Dingye biotech building block D Room 308 False: Nanjing Mclean biological medicine technology Co., Ltd.|Spark Road 210032 Jiangsu province Nanjing city high tech Development Zone No. 10 Dingye biotech building block D Room 308 Number: 48 Volume: 32 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151209 Assignee: Jiangsu Kede Biological Medicine Technology Co Ltd Assignor: NANJING MAIKELIN BIOMEDICAL TECHNOLOGY CO., LTD. Contract record no.: 2016320000223 Denomination of invention: Application of monoclonal antibody NJ001-1 to preparation of drug for inhibiting invasion and metastasis of NSCLC (non-small-cell lung cancer) License type: Common License Record date: 20161130 |
|
| ERR | Gazette correction | ||
| GR01 | Patent grant | ||
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151209 Assignee: Jiangsu Kede Biological Medicine Technology Co Ltd Assignor: NANJING MAIKELIN BIOMEDICAL TECHNOLOGY CO., LTD. Contract record no.: 2017320000009 Denomination of invention: Application of monoclonal antibody NJ001-1 to preparation of drug for inhibiting invasion and metastasis of NSCLC (non-small-cell lung cancer) Granted publication date: 20161228 License type: Common License Record date: 20170215 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jiangsu Kede Biological Medicine Technology Co Ltd Assignor: NANJING MAIKELIN BIOMEDICAL TECHNOLOGY CO., LTD. Contract record no.: 2016320000223 Date of cancellation: 20170406 |
|
| EC01 | Cancellation of recordation of patent licensing contract |